The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics.
Phathom Pharmaceuticals Announces Pricing of Initial Public Offering
AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma
CutisPharma Announces Acquisition of Silvergate Pharmaceuticals, Name Change to Azurity Pharmaceuticals
Passage Bio Launches with $115.5 Million Series A to Develop AAV-Delivered Therapeutics to Treat Rare Monogenic CNS Diseases